Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates...
3 insider purchases on record · latest filing 2006-05-15.
Insiders have also filed 3 sale transactions at HELX.